Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Equity Average (2020 - 2025)

Lyell Immunopharma's Equity Average history spans 6 years, with the latest figure at $317.7 million for Q2 2025.

  • For Q2 2025, Equity Average fell 45.67% year-over-year to $317.7 million; the TTM value through Jun 2025 reached $317.7 million, down 45.67%, while the annual FY2024 figure was $518.9 million, 30.27% down from the prior year.
  • Equity Average for Q2 2025 was $317.7 million at Lyell Immunopharma, down from $359.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.0 billion in Q3 2021 and bottomed at -$313.3 million in Q1 2021.
  • The 5-year median for Equity Average is $696.7 million (2023), against an average of $627.9 million.
  • The largest annual shift saw Equity Average surged 496.33% in 2021 before it tumbled 45.67% in 2025.
  • A 5-year view of Equity Average shows it stood at $958.1 million in 2021, then fell by 13.72% to $826.6 million in 2022, then decreased by 18.19% to $676.3 million in 2023, then plummeted by 32.46% to $456.8 million in 2024, then tumbled by 30.44% to $317.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Equity Average are $317.7 million (Q2 2025), $359.7 million (Q1 2025), and $456.8 million (Q4 2024).